Cyclopharm Limited provided sales guidance for the half year ended 30 June 2022. The company expected revenue is expected to be approximately $11.3 million, 36% higher than pcp and 74% higher than the company's pre-COVID revenues in first half 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 AUD | -0.65% | -1.28% | -20.00% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.00% | 111M | |
+10.16% | 189B | |
+26.21% | 150B | |
+32.78% | 113B | |
+1.98% | 65.05B | |
+14.48% | 52.83B | |
+2.92% | 49.39B | |
-6.60% | 38.1B | |
-1.07% | 35.14B | |
+23.08% | 31.2B |
- Stock Market
- Equities
- CYC Stock
- News Cyclopharm Limited
- Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022